Stockholders Back Reverse Split, Warrant Repricing, and Equity Plan Expansion at VivoSim
VIVS is trading near its 52-week low of $0.191 (5.5% above the low) on light trading volume (0.1× avg).
Summary
At the September 30 annual meeting, VivoSim Labs stockholders approved a reverse stock split, a 3.165M share equity plan increase, and warrant-related items, advancing the company's Nasdaq compliance and capital restructuring efforts.
Key Events · Corporate Governance and Compliance · VIVS
-
Reverse Stock Split Approved
Stockholders approved a reverse split at a ratio of 1-to-5 to 1-to-20, with Board discretion to implement any time on or before September 30, 2027, to regain Nasdaq's $1 minimum bid price compliance.
-
Warrant Exercise Price Reduced
Stockholders approved reducing the exercise price of May 13, 2024 warrants from $9.60 to $0.85 per share, aligning with the July 2026 private placement terms.
-
4.7M Shares Authorized for Warrant Exercise
Stockholders approved the issuance of 4,705,883 shares upon exercise of warrants issued in the July 2026 private placement, a significant potential dilution to existing holders.
-
Equity Plan Increased by 3.165M Shares
Stockholders approved an amendment to the 2022 Equity Incentive Plan increasing the share reserve by 3,165,000 shares for future equity awards.
Analysis · VIVS · Life Sciences
At the September 30 annual meeting, VivoSim Labs stockholders approved a reverse stock split at a ratio of 1-to-5 to 1-to-20, with the Board retaining discretion to implement it any time before September 30, 2027. The vote also authorized the issuance of 4,705,883 shares upon exercise of July 2026 private placement warrants and reduced the exercise price of May 2024 warrants from $9.60 to $0.85 per share. These approvals are critical for the company's Nasdaq compliance strategy: the reverse split is designed to lift the stock price above the $1 minimum bid requirement, while the warrant repricing and share issuance address the company's capital structure and going concern risk.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VIVS was trading at $0.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.19 to $3.54. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.